keyword
MENU ▼
Read by QxMD icon Read
search

systemic lupus erythematosus guidelines

keyword
https://www.readbyqxmd.com/read/27878954/biomarkers-of-systemic-lupus-erythematosus-identified-using-mass-spectrometry-based-proteomics-a-systematic-review
#1
REVIEW
Orthodoxia Nicolaou, Andreas Kousios, Andreas Hadjisavvas, Bernard Lauwerys, Kleitos Sokratous, Kyriacos Kyriacou
Advances in mass spectrometry technologies have created new opportunities for discovering novel protein biomarkers in systemic lupus erythematosus (SLE). We performed a systematic review of published reports on proteomic biomarkers identified in SLE patients using mass spectrometry-based proteomics and highlight their potential disease association and clinical utility. Two electronic databases, MEDLINE and EMBASE, were systematically searched up to July 2015. The methodological quality of studies included in the review was performed according to Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines...
November 23, 2016: Journal of Cellular and Molecular Medicine
https://www.readbyqxmd.com/read/27859683/s2k-guideline-for-treatment-of-cutaneous-lupus-erythematosus
#2
Annegret Kuhn, Elisabeth Aberer, Zsuzsanna Bata-Csörgő, Marzia Caproni, Andreas Dreher, Camille Frances, Regine Gläser, Hans-Wilhelm Klötgen, Aysche Landmann, Branka Marinovic, Filippa Nyberg, Rodica Olteanu, Annamari Ranki, Jacek C Szepietowski, Beatrix Volc-Platzer
Cutaneous lupus erythematosus (CLE) is a rare inflammatory autoimmune disease with heterogeneous subtypes. To date, no therapeutic agents have been licensed specifically for patients with this disease entity and topical and systemic drugs are mostly used "off-label". The aim of the present guideline was to achieve a broad consensus on treatment strategies for patients with CLE by a European subcommittee, guided by the European Dermatology Forum (EDF) and supported by the European Academy of Dermatology and Venereology (EADV)...
November 15, 2016: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/27855151/advances-in-the-care-of-children-with-lupus-nephritis
#3
Scott E Wenderfer, Natasha M Ruth, Hermine I Brunner
The care of children with lupus nephritis (LN) has changed dramatically over the past 50 years. The majority of patients with childhood-onset systemic lupus erythematosus (cSLE) develop LN. In the 1960's, prognosis in children was worse than in adults; therapies were limited and toxic. Nearly half of cases resulted in death within 2-years. Since this time, several diagnostic recommendations and disease-specific indices have been developed to assist physicians caring for patients with LN. Pediatric researchers are validating and adapting these indices and guidelines for the treatment of LN in cSLE...
November 17, 2016: Pediatric Research
https://www.readbyqxmd.com/read/27816371/systemic-lupus-erythematosus-case-definition-and-guidelines-for-data-collection-analysis-and-presentation-of-immunization-safety-data
#4
Aimee O Hersh, Graciela S Alarcón, Caterina Bonetto, Yolanda Brauchli Pernus, Merita Kucuku, Carmela Santuccio, Saša Živković, Jan Bonhoeffer
No abstract text is available yet for this article.
December 12, 2016: Vaccine
https://www.readbyqxmd.com/read/27777394/systemic-lupus-erythematosus-presenting-as-refractory-thrombotic-thrombocytopenic-purpura-a-diagnostic-and-management-challenge-a-case-report-and-concise-review-of-the-literature
#5
Mohammad Abu-Hishmeh, Alamgir Sattar, Fnu Zarlasht, Mohamed Ramadan, Aisha Abdel-Rahman, Shante Hinson, Caroline Hwang
BACKGROUND Thrombotic thrombocytopenic purpura (TTP) is one of the thrombotic microangiopathic (TMA) syndromes, caused by severely reduced activity of the vWF-cleaving protease ADAMTS13. Systemic lupus erythematosus (SLE), on the other hand, is an autoimmune disease that affects various organs in the body, including the hematopoietic system. SLE can present with TMA, and differentiating between SLE and TTP in those cases can be very challenging, particularly in patients with no prior history of SLE. Furthermore, an association between these 2 diseases has been described in the literature, with most of the TTP cases occurring after the diagnosis of SLE...
October 25, 2016: American Journal of Case Reports
https://www.readbyqxmd.com/read/27703053/gestational-weight-gain-in-women-with-systemic-lupus-erythematosus
#6
A M Eudy, A M Siega-Riz, S M Engel, N Franceschini, A G Howard, M E B Clowse, M Petri
OBJECTIVE: The objective of this study was to estimate the proportion of pregnant women with systemic lupus erythematosus meeting Institute of Medicine guidelines for gestational weight gain and determine correlates of adherence to guidelines. METHODS: Singleton, live births in the Hopkins Lupus Pregnancy Cohort 1987-2015 were included. Pre-pregnancy weight was the weight recorded 12 months prior to pregnancy/first trimester. Final weight was the last weight recorded in the third trimester...
October 4, 2016: Lupus
https://www.readbyqxmd.com/read/27676644/novel-enzyme-immunoassay-system-for-simultaneous-detection-of-six-subclasses-of-antiphospholipid-antibodies-for-differential-diagnosis-of-antiphospholipid-syndrome
#7
Junzo Nojima, Yukari Motoki, Kazusa Hara, Toshiyuki Sakata, Kiyoshi Ichihara
Antiphospholipid syndrome, which often complicates systemic lupus erythematosus (SLE), features high occurrence of arterial and/or venous thrombosis and recurrent fetal loss. However, which antibody subclass contributes to which clinical event remains uncertain. We newly developed an up-to-date enzyme immunoassay system using the AcuStar automated analyzer (Instrumentation Laboratory, Bedford, Massachusetts, USA) for parallel detection of six subclasses of antiphospholipid antibodies (aPLs): anticardiolipin antibodies (aCL) of IgG, IgM, and IgA and anti-β2-glycoprotein I antibodies (aβ2GPI) of IgG, IgM, and IgA...
September 24, 2016: Blood Coagulation & Fibrinolysis: An International Journal in Haemostasis and Thrombosis
https://www.readbyqxmd.com/read/27569461/-clinical-guideline-for-the-treatment-of-lupus-nephritis-and-single-centre-results-of-mycofenolate-mofetil-among-patients-with-lupus-nephritis-in-the-national-institute-of-rheumatology-and-physiotherapy-budapest
#8
Melinda Zsuzsanna Szabó, Emese Kiss
The authors present the latest guideline for the treatment of lupus nephritis and their own single-centre results with mycofenolate mofetil treated lupus nephritis. Lupus nephritis and mainly its proliferative form is a frequent and potentially life-threatening manifestation of systemic lupus erythematosus that can lead to end-stage renal disease. The treatment of lupus nephritis greatly improved in the last decades; mycofenolate mofetil has become an alternative of cyclophosphamide both in remission induction and as a maintenance regimen as well in the treatment of Class III and IV glomerulonephritis...
August 2016: Orvosi Hetilap
https://www.readbyqxmd.com/read/27529058/current-and-emerging-treatment-options-in-the-management-of-lupus
#9
REVIEW
Natasha Jordan, David D'Cruz
Systemic lupus erythematosus (SLE) is a complex autoimmune disease with variable clinical manifestations. While the clearest guidelines for the treatment of SLE exist in the context of lupus nephritis, patients with other lupus manifestations such as neuropsychiatric, hematologic, musculoskeletal, and severe cutaneous lupus frequently require immunosuppression and/or biologic therapy. Conventional immunosuppressive agents such as mycophenolate mofetil, azathioprine, and cyclophosphamide are widely used in the management of SLE with current more rationalized treatment regimens optimizing the use of these agents while minimizing potential toxicity...
2016: ImmunoTargets and Therapy
https://www.readbyqxmd.com/read/27514195/-rheumatology-progress-in-diagnosis-and-treatments-topics-iv-collagen-diseases-except-for-rheumatoid-arthritis-and-hot-topics-1-systemic-lupus-erythematosus
#10
REVIEW
Naoto Tamura
No abstract text is available yet for this article.
October 10, 2014: Nihon Naika Gakkai Zasshi. the Journal of the Japanese Society of Internal Medicine
https://www.readbyqxmd.com/read/27497258/improved-strategies-for-designing-lupus-trials-with-targeted-therapies-learning-from-65-years-of-experience
#11
D J Wallace
The development of new agents to manage lupus erythematosus has lagged behind other autoimmune rheumatic diseases. This is in large part because lupus is a heterogeneous disorder affecting nine principal domains (organ systems) that are difficult to measure and quantify and can be at variance with each other. Over the last two decades, a variety of guidelines, definitions, candidate surrogate or biomarkers, metrics and composite indices have been presented as benchmarks that can be utilized to assess lupus in clinical trials...
September 2016: Lupus
https://www.readbyqxmd.com/read/27391903/retinal-toxicity-induced-by-antimalarial-drugs-literature-review-and-case-report
#12
Manuel Garza-Leon, Diana Elsa Flores-Alvarado, Juan Manuel Muñoz-Bravo
Antimalarial drugs are widely used in several countries for control of rheumatologic diseases such as systemic lupus erythematosus and rheumatoid arthritis. They are still used in Mexico because of their low cost and few secondary effects, most of which are mild and reversible. Even so, at an ophthalmological level, they could produce irreversible visual damage, which is why it is important to have ophthalmological evaluation and proper follow up. We present a clinical case as an example of characteristic ophthalmological findings as well as risk factors for retinal toxicity...
2016: Medwave
https://www.readbyqxmd.com/read/27390939/left-ventricular-diastolic-dysfunction-and-increased-left-ventricular-mass-index-related-to-pulmonary-hypertension-in-patients-with-systemic-autoimmune-disease-without-pericardial-effusion
#13
Atsushi Sugiura, Nobusada Funabashi, Koya Ozawa, Yoshio Kobayashi
PURPOSE: We investigated the relationship of left ventricular (LV) diastolic dysfunction and LV mass index (LVMI) against pulmonary hypertension (PH) in systemic autoimmune disease (SAD). METHODS: A total of 84 SAD patients (68 females; 53±17years; systemic lupus erythematosus, 27%; scleroderma, 17%; vasculitis, 16%; mixed connective tissue disease, 13% and polymyositis/dermatomyositis complex, 10%) without significant pericardial effusion (PE) on TTE (Vivid E9, GE) were analyzed...
October 1, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/27344205/insights-into-the-epidemiology-and-management%C3%A2-of%C3%A2-lupus-nephritis-from-the%C3%A2-us%C3%A2-rheumatologist-s-perspective
#14
Paul J Hoover, Karen H Costenbader
Lupus nephritis is a common and severe manifestation of systemic lupus erythematosus that disproportionately affects nonwhites and those in lower socioeconomic groups. This review discusses recent data on the incidence, prevalence, and outcomes of patients with lupus nephritis with a focus on low-income US Medicaid patients. We also review recent guidelines on diagnosis, treatment, and screening for new onset and relapses of lupus nephritis. Finally, we discuss the management of lupus nephritis from a rheumatologist's perspective, including vigilance for the common adverse events related to disease and treatment, and we review prevention and new treatment strategies...
September 2016: Kidney International
https://www.readbyqxmd.com/read/27082556/refractory-genital-hpv-infection-and-adult-onset-still-disease-a-case-report-and-literature-review
#15
Xin Yu, Heyi Zheng
Adult-onset Still disease (AOSD) is a systemic autoimmune disease (AIID) that can develop after exposure to infectious agents. Genital human papillomavirus (HPV) infection has been reported to induce or exacerbate AIIDs, such as systemic lupus erythematosus (SLE). No guidelines are available for the management of genital warts in AOSD. Case report and literature review. We report a patient who was diagnosed AOSD in the setting of refractory and recurrent genital HPV infection, demonstrating a possible link between HPV infection and AOSD...
April 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27058995/reduced-aerobic-capacity-and-quality-of-life-in-physically-inactive-patients-with-systemic-lupus-erythematosus-with-mild-or-inactive-disease
#16
Ana J Pinto, Cintia N H Miyake, Fabiana B Benatti, Clovis A Silva, Adriana M E Sallum, Eduardo Borba, Ana L de Sá-Pinto, Eloisa Bonfá, Bruno Gualano
OBJECTIVE: To compare aerobic capacity and health-related quality of life (HRQOL) in physically inactive adult systemic lupus erythematosus (A-SLE) and childhood-onset systemic lupus erythematosus (C-SLE) patients with mild/inactive disease versus healthy controls. METHODS: In a cross-sectional study, 39 patients (C-SLE: n = 18, ages 9-18 years; and A-SLE: n = 21, ages 23-45 years) with inactive disease activity (Systemic Lupus Erythematosus Disease Activity Index ≤4) and low cumulative damage (Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index ≤2) and 30 healthy controls (15 children and adolescents [C-CTRL], 15 adults [A-CTRL]) matched by physical inactivity, age, sex, and body mass index (BMI) were assessed for aerobic capacity and HRQOL...
April 5, 2016: Arthritis Care & Research
https://www.readbyqxmd.com/read/26977832/diagnosis-and-management-of-nephrotic-syndrome-in-adults
#17
Charles Kodner
Nephrotic syndrome (NS) consists of peripheral edema, heavy proteinuria, and hypoalbuminemia, often with hyperlipidemia. Patients typically present with edema and fatigue, without evidence of heart failure or severe liver disease. The diagnosis of NS is based on typical clinical features with confirmation of heavy proteinuria and hypoalbuminemia. The patient history and selected diagnostic studies rule out important secondary causes, including diabetes mellitus, systemic lupus erythematosus, and medication adverse effects...
March 15, 2016: American Family Physician
https://www.readbyqxmd.com/read/26975887/-clinical-practice-guidelines-for-systemic-lupus-erythematosus-recommendations-for-general-clinical-management
#18
María M Trujillo-Martín, Iñigo Rúa-Figueroa Fernández de Larrinoa, Guillermo Ruíz-Irastorza, José María Pego-Reigosa, José Mario Sabio Sánchez, Pedro Serrano-Aguilar
Systemic lupus erythematosus (SLE) is a complex rheumatic multisystemic disease of autoimmune origin with significant potential morbidity and mortality. It is one of the most common autoimmune diseases with an estimated prevalence of 20-150 cases per 100,000 inhabitants. The clinical spectrum of SLE is wide and variable both in clinical manifestations and severity. This prompted the Spanish Ministry of Health, Social Services and Equality to promote and fund the development of a clinical practice guideline (CPG) for the clinical care of SLE patients within the Programme of CPG in the National Health System which coordinates GuiaSalud...
May 6, 2016: Medicina Clínica
https://www.readbyqxmd.com/read/26972733/the-wound-burn-guidelines-4-guidelines-for-the-management-of-skin-ulcers-associated-with-connective-tissue-disease-vasculitis
#19
Manabu Fujimoto, Yoshihide Asano, Takayuki Ishii, Fumihide Ogawa, Tamihiro Kawakami, Masanari Kodera, Masatoshi Abe, Taiki Isei, Takaaki Ito, Yuji Inoue, Shinichi Imafuku, Ryokichi Irisawa, Masaki Ohtsuka, Mikio Ohtsuka, Takafumi Kadono, Masakazu Kawaguchi, Ryuichi Kukino, Takeshi Kono, Keisuke Sakai, Masakazu Takahara, Miki Tanioka, Takeshi Nakanishi, Yasuhiro Nakamura, Akira Hashimoto, Minoru Hasegawa, Masahiro Hayashi, Hiroshi Fujiwara, Takeo Maekawa, Koma Matsuo, Naoki Madokoro, Osamu Yamasaki, Yuichiro Yoshino, Andres Le Pavoux, Takao Tachibana, Hironobu Ihn
The Japanese Dermatological Association prepared guidelines focused on the treatment of skin ulcers associated with connective tissue disease/vasculitis practical in clinical settings of dermatological care. Skin ulcers associated with connective tissue diseases or vasculitis occur on the background of a wide variety of diseases including, typically, systemic sclerosis but also systemic lupus erythematosus (SLE), dermatomyositis, rheumatoid arthritis (RA), various vasculitides and antiphospholipid antibody syndrome (APS)...
July 2016: Journal of Dermatology
https://www.readbyqxmd.com/read/26971103/pharmacological-management-of-childhood-onset-systemic-lupus-erythematosus
#20
REVIEW
Colin Thorbinson, Louise Oni, Eve Smith, Angela Midgley, Michael W Beresford
Systemic lupus erythematosus (SLE) is a rare, severe, multisystem autoimmune disorder. Childhood-onset SLE (cSLE) follows a more aggressive course with greater associated morbidity and mortality than adult-onset SLE. Its aetiology is yet to be fully elucidated. It is recognised to be the archetypal systemic autoimmune disease, arising from a complex interaction between the innate and adaptive immune systems. Its complexity is reflected by the fact that there has been only one new drug licensed for use in SLE in the last 50 years...
June 2016: Paediatric Drugs
keyword
keyword
119658
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"